Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

26 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Discovery of Sulanemadlin (ALRN-6924), the First Cell-Permeating, Stabilized α-Helical Peptide in Clinical Development.
Guerlavais V, Sawyer TK, Carvajal L, Chang YS, Graves B, Ren JG, Sutton D, Olson KA, Packman K, Darlak K, Elkin C, Feyfant E, Kesavan K, Gangurde P, Vassilev LT, Nash HM, Vukovic V, Aivado M, Annis DA. Guerlavais V, et al. Among authors: annis da. J Med Chem. 2023 Jul 27;66(14):9401-9417. doi: 10.1021/acs.jmedchem.3c00623. Epub 2023 Jul 13. J Med Chem. 2023. PMID: 37439511
Tubulin Carboxypeptidase Activity Promotes Focal Gelatin Degradation in Breast Tumor Cells and Induces Apoptosis in Breast Epithelial Cells That Is Overcome by Oncogenic Signaling.
Mathias TJ, Ju JA, Lee RM, Thompson KN, Mull ML, Annis DA, Chang KT, Ory EC, Stemberger MB, Hotta T, Ohi R, Vitolo MI, Moutin MJ, Martin SS. Mathias TJ, et al. Among authors: annis da. Cancers (Basel). 2022 Mar 28;14(7):1707. doi: 10.3390/cancers14071707. Cancers (Basel). 2022. PMID: 35406479 Free PMC article.
Correction: Phase I Trial of ALRN-6924, a Dual Inhibitor of MDMX and MDM2, in Patients with Solid Tumors and Lymphomas Bearing Wild-type TP53.
Saleh MN, Patel MR, Bauer TM, Goel S, Falchook GS, Shapiro GI, Chung KY, Infante JR, Conry RM, Rabinowits G, Hong DS, Wang JS, Steidl U, Walensky LD, Naik G, Guerlavais V, Vukovic V, Annis DA, Aivado M, Meric-Bernstam F. Saleh MN, et al. Among authors: annis da. Clin Cancer Res. 2022 Jan 15;28(2):429. doi: 10.1158/1078-0432.CCR-21-4241. Clin Cancer Res. 2022. PMID: 35045962 Free PMC article. No abstract available.
Author Correction: MDM4 inhibition: a novel therapeutic strategy to reactivate p53 in hepatoblastoma.
Woodfield SE, Shi Y, Patel RH, Chen Z, Shah AP, Srivastava RK, Whitlock RS, Ibarra AM, Larson SR, Sarabia SF, Badachhape A, Starosolski Z, Ghaghada KB, Sumazin P, Annis DA, López-Terrada D, Vasudevan SA. Woodfield SE, et al. Among authors: annis da. Sci Rep. 2021 Oct 1;11(1):19916. doi: 10.1038/s41598-021-98174-7. Sci Rep. 2021. PMID: 34599198 Free PMC article. No abstract available.
Phase 1 Trial of ALRN-6924, a Dual Inhibitor of MDMX and MDM2, in Patients with Solid Tumors and Lymphomas Bearing Wild-type TP53.
Saleh MN, Patel MR, Bauer TM, Goel S, Falchook GS, Shapiro GI, Chung KY, Infante JR, Conry RM, Rabinowits G, Hong DS, Wang JS, Steidl U, Naik G, Guerlavais V, Vukovic V, Annis DA, Aivado M, Meric-Bernstam F. Saleh MN, et al. Among authors: annis da. Clin Cancer Res. 2021 Oct 1;27(19):5236-5247. doi: 10.1158/1078-0432.CCR-21-0715. Clin Cancer Res. 2021. PMID: 34301750 Free PMC article. Clinical Trial.
MDM4 inhibition: a novel therapeutic strategy to reactivate p53 in hepatoblastoma.
Woodfield SE, Shi Y, Patel RH, Chen Z, Shah AP, Srivastava RK, Whitlock RS, Ibarra AM, Larson SR, Sarabia SF, Badachhape A, Starosolski Z, Ghaghada KB, Sumazin P, Annis DA, López-Terrada D, Vasudevan SA. Woodfield SE, et al. Among authors: annis da. Sci Rep. 2021 Feb 3;11(1):2967. doi: 10.1038/s41598-021-82542-4. Sci Rep. 2021. PMID: 33536467 Free PMC article.
26 results